Market LIVE
Published markets; coverage varies by country
Product profile · United States

APTIOM

 ·  Patent Litigation & Settlement History ↓

IngredientESLICARBAZEPINE ACETATE
Application typeNDA
Application022416
Product004
Dosage formTABLET
RouteORAL
Strength800MG
Approval date2013-11-08
Marketing statusPrescription
Status event—
ApplicantSUMITOMO PHARMA AM
Product source

Current GenericRadar decision

Year2021
SelectionEXISTING_GENERIC
ReviewDISQUALIFIED
Anchor typeFINAL_ANDA
Anchor date2021-06-29
Patent anchor—
Exclusivity anchor—
Protection date—
First Final ANDA2021-06-29
Status event—

Exact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.

Patent estate

PatentEffective dateOfficial listingTRUE_DSDS gradeClaim classification / basisPTEPEDFamily
92061352026-04-21DS ————
———
96439292026-04-21DP ————
———
97639542028-09-13U U-2123———
———
109127812028-10-23DP ————
———
95662442028-10-23DP ————
———
83724312030-04-17DP ————
———
97507472032-08-24U U-2121———
———
97507472032-08-24U U-2041———
———

Regulatory exclusivity

CodeStart dateEnd dateScopeEntire productAll indicationsFull coverage dateCombinationSource
No exclusivity facts are recorded in this product snapshot.

2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE

Generic approval evidence

Application / productEventFinal dateTentative dateApplicantAuthorized genericExact mappingSource
211238 / 004FINAL_APPROVAL · FINAL_APPROVED2021-06-29—DR REDDYS LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211186 / 004FINAL_APPROVAL · FINAL_APPROVED2023-08-03—HETERO LABS LTD UNIT VNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211199 / 004FINAL_APPROVAL · FINAL_APPROVED2023-10-06—ALKEM LABORATORIES LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211236 / 004FINAL_APPROVAL · FINAL_APPROVED2023-12-07—APOTEX INCNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211227 / 004FINAL_APPROVAL · FINAL_APPROVED2024-02-27—TORRENT PHARMACEUTICALS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211246 / 004FINAL_APPROVAL · FINAL_APPROVED2024-03-27—LUPIN LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211219 / 004FINAL_APPROVAL · FINAL_APPROVED2025-08-04—JUBILANT GENERICS LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
211247 / 004FINAL_APPROVAL · FINAL_APPROVED2025-11-03—SPH ZHONGXI PHARMACEUTICAL CO LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource
216481 / 004FINAL_APPROVAL · FINAL_APPROVED2026-08-05—AUROBINDO PHARMA LTDNEXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource

Market Entry Information

API filings, authorized generics and linked regulatory milestones.

API Master Files & Certifications 0 records

Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.

APIHolder / manufacturerHolder countryFiling typeNumberStatusFiled dateAvailable for referenceSourceLast verified
No master-file or certification records are linked through public manufacturer portfolios.

Authorized Generics 0 records

Authorized generics are shown separately from independent ANDA approvals.

Application / productApplicantEvent / status First marketed Product mappingSourceLast verified
No authorized-generic records are linked to this product.

Tentative ANDA Approvals 0 records

Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.

Application / productApplicantEvent / status Tentative date Follow-up final approvalProduct mappingSourceLast verified
No tentative-approval records are linked to this product.

Paragraph IV Challenges 0 records

Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.

Application / productApplicantEvent / status Certification event date Product mappingSourceLast verified
No structured Paragraph IV certification events are linked in the available approval evidence.

Final ANDA Approvals 9 records

Approval dates do not establish commercial launch. Product mapping is shown for each linked record.

Application / productApplicantEvent / status Final approval date Product mappingSourceLast verified
211238 / 004DR REDDYS LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2021-06-29 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211186 / 004HETERO LABS LTD UNIT VFINAL_APPROVAL · FINAL_APPROVED2023-08-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211199 / 004ALKEM LABORATORIES LTDFINAL_APPROVAL · FINAL_APPROVED2023-10-06 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211236 / 004APOTEX INCFINAL_APPROVAL · FINAL_APPROVED2023-12-07 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211227 / 004TORRENT PHARMACEUTICALS LTDFINAL_APPROVAL · FINAL_APPROVED2024-02-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211246 / 004LUPIN LTDFINAL_APPROVAL · FINAL_APPROVED2024-03-27 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211219 / 004JUBILANT GENERICS LTDFINAL_APPROVAL · FINAL_APPROVED2025-08-04 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
211247 / 004SPH ZHONGXI PHARMACEUTICAL CO LTDFINAL_APPROVAL · FINAL_APPROVED2025-11-03 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
216481 / 004AUROBINDO PHARMA LTDFINAL_APPROVAL · FINAL_APPROVED2026-08-05 EXACT_PRODUCT · PENDING_PRODUCT_MAPPINGSource—
Decision evidence (1)
TypeDateRoleBasisSource
GENERIC2021-06-29TERMINAL_GENERIC_BASISExact product/strength Final ANDA confirmed. Date is earliest verified official product approval for the batch. AG and tentative excluded. Approval date is not commercial launch date. No DS classification asserted.Source
Independent legal-event information

Litigation & Settlement History

Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.

No litigation or settlement record currently linked to this product.